Cargando…

Pharmacokinetics and bioavailability of oxycodone and acetaminophen following single-dose administration of MNK-795, a dual-layer biphasic IR/ER combination formulation, under fed and fasted conditions

BACKGROUND: XARTEMIS™ XR (formerly MNK-795) is a combination oxycodone (OC) and acetaminophen (APAP) analgesic with both immediate-release and extended-release (ER) components (ER OC/APAP). The tablets are designed with gastric-retentive ER oral delivery technology that releases the ER component at...

Descripción completa

Detalles Bibliográficos
Autores principales: Devarakonda, Krishna, Morton, Terri, Margulis, Rachel, Giuliani, Michael, Barrett, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4145823/
https://www.ncbi.nlm.nih.gov/pubmed/25170252
http://dx.doi.org/10.2147/DDDT.S64261
_version_ 1782332225909424128
author Devarakonda, Krishna
Morton, Terri
Margulis, Rachel
Giuliani, Michael
Barrett, Thomas
author_facet Devarakonda, Krishna
Morton, Terri
Margulis, Rachel
Giuliani, Michael
Barrett, Thomas
author_sort Devarakonda, Krishna
collection PubMed
description BACKGROUND: XARTEMIS™ XR (formerly MNK-795) is a combination oxycodone (OC) and acetaminophen (APAP) analgesic with both immediate-release and extended-release (ER) components (ER OC/APAP). The tablets are designed with gastric-retentive ER oral delivery technology that releases the ER component at a controlled rate in the upper gastrointestinal tract. Because consumption of food has demonstrated an impact on the pharmacokinetics (PK) of some marketed products using gastric-retentive ER oral delivery technology, a characterization of the effects of fed (high- and low-fat diets) versus fasted conditions on the PK of ER OC/APAP was performed. METHODS: This Phase I study used an open-label randomized single-dose three-period six-sequence crossover single-center design. Healthy adult participants (n=48) were randomized to receive two tablets of ER OC/APAP under three conditions: following a high-fat meal; following a low-fat meal; and fasted. Plasma concentration versus time data from predose throughout designated times up to 48 hours postdose was used to estimate the PK parameters of oxycodone and APAP. RESULTS: Thirty-one participants completed all three treatment periods. Both oxycodone and APAP were rapidly absorbed under fasted conditions. Total oxycodone and APAP exposures (area under the plasma drug concentration-time curve [AUC]) from ER OC/APAP were not significantly affected by food, and minimal changes to maximum observed plasma concentration for oxycodone and APAP were also noted. However, food marginally delayed the time to maximum observed plasma concentration of oxycodone and APAP. There was no indication that tolerability was affected by food. CONCLUSION: The findings from this study suggest that ER OC/APAP can be administered with or without food.
format Online
Article
Text
id pubmed-4145823
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-41458232014-08-28 Pharmacokinetics and bioavailability of oxycodone and acetaminophen following single-dose administration of MNK-795, a dual-layer biphasic IR/ER combination formulation, under fed and fasted conditions Devarakonda, Krishna Morton, Terri Margulis, Rachel Giuliani, Michael Barrett, Thomas Drug Des Devel Ther Original Research BACKGROUND: XARTEMIS™ XR (formerly MNK-795) is a combination oxycodone (OC) and acetaminophen (APAP) analgesic with both immediate-release and extended-release (ER) components (ER OC/APAP). The tablets are designed with gastric-retentive ER oral delivery technology that releases the ER component at a controlled rate in the upper gastrointestinal tract. Because consumption of food has demonstrated an impact on the pharmacokinetics (PK) of some marketed products using gastric-retentive ER oral delivery technology, a characterization of the effects of fed (high- and low-fat diets) versus fasted conditions on the PK of ER OC/APAP was performed. METHODS: This Phase I study used an open-label randomized single-dose three-period six-sequence crossover single-center design. Healthy adult participants (n=48) were randomized to receive two tablets of ER OC/APAP under three conditions: following a high-fat meal; following a low-fat meal; and fasted. Plasma concentration versus time data from predose throughout designated times up to 48 hours postdose was used to estimate the PK parameters of oxycodone and APAP. RESULTS: Thirty-one participants completed all three treatment periods. Both oxycodone and APAP were rapidly absorbed under fasted conditions. Total oxycodone and APAP exposures (area under the plasma drug concentration-time curve [AUC]) from ER OC/APAP were not significantly affected by food, and minimal changes to maximum observed plasma concentration for oxycodone and APAP were also noted. However, food marginally delayed the time to maximum observed plasma concentration of oxycodone and APAP. There was no indication that tolerability was affected by food. CONCLUSION: The findings from this study suggest that ER OC/APAP can be administered with or without food. Dove Medical Press 2014-08-19 /pmc/articles/PMC4145823/ /pubmed/25170252 http://dx.doi.org/10.2147/DDDT.S64261 Text en © 2014 Devarakonda et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Devarakonda, Krishna
Morton, Terri
Margulis, Rachel
Giuliani, Michael
Barrett, Thomas
Pharmacokinetics and bioavailability of oxycodone and acetaminophen following single-dose administration of MNK-795, a dual-layer biphasic IR/ER combination formulation, under fed and fasted conditions
title Pharmacokinetics and bioavailability of oxycodone and acetaminophen following single-dose administration of MNK-795, a dual-layer biphasic IR/ER combination formulation, under fed and fasted conditions
title_full Pharmacokinetics and bioavailability of oxycodone and acetaminophen following single-dose administration of MNK-795, a dual-layer biphasic IR/ER combination formulation, under fed and fasted conditions
title_fullStr Pharmacokinetics and bioavailability of oxycodone and acetaminophen following single-dose administration of MNK-795, a dual-layer biphasic IR/ER combination formulation, under fed and fasted conditions
title_full_unstemmed Pharmacokinetics and bioavailability of oxycodone and acetaminophen following single-dose administration of MNK-795, a dual-layer biphasic IR/ER combination formulation, under fed and fasted conditions
title_short Pharmacokinetics and bioavailability of oxycodone and acetaminophen following single-dose administration of MNK-795, a dual-layer biphasic IR/ER combination formulation, under fed and fasted conditions
title_sort pharmacokinetics and bioavailability of oxycodone and acetaminophen following single-dose administration of mnk-795, a dual-layer biphasic ir/er combination formulation, under fed and fasted conditions
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4145823/
https://www.ncbi.nlm.nih.gov/pubmed/25170252
http://dx.doi.org/10.2147/DDDT.S64261
work_keys_str_mv AT devarakondakrishna pharmacokineticsandbioavailabilityofoxycodoneandacetaminophenfollowingsingledoseadministrationofmnk795aduallayerbiphasicirercombinationformulationunderfedandfastedconditions
AT mortonterri pharmacokineticsandbioavailabilityofoxycodoneandacetaminophenfollowingsingledoseadministrationofmnk795aduallayerbiphasicirercombinationformulationunderfedandfastedconditions
AT margulisrachel pharmacokineticsandbioavailabilityofoxycodoneandacetaminophenfollowingsingledoseadministrationofmnk795aduallayerbiphasicirercombinationformulationunderfedandfastedconditions
AT giulianimichael pharmacokineticsandbioavailabilityofoxycodoneandacetaminophenfollowingsingledoseadministrationofmnk795aduallayerbiphasicirercombinationformulationunderfedandfastedconditions
AT barrettthomas pharmacokineticsandbioavailabilityofoxycodoneandacetaminophenfollowingsingledoseadministrationofmnk795aduallayerbiphasicirercombinationformulationunderfedandfastedconditions